Results 131 to 140 of about 2,224,846 (160)

Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells. [PDF]

Onco Targets Ther, 2018
Huang K, Liu D.
europepmc   +1 more source

Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation-Mediated Erlotinib Resistance After Failure of Chemotherapy. [PDF]

JTO Clin Res Rep, 2020
Zhou Y, Zeng L, Yang N, Zhang Y.
europepmc   +1 more source

Correction to "Increased Expression of miR-641 Contributes to Erlotinib Resistance in Non-Small-Cell Lung Cancer Cells by Targeting NF1". [PDF]

Cancer Med
europepmc   +1 more source

Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas. [PDF]

Theranostics, 2019
Lei HM, Zhang KR, Wang CH, Wang Y, Zhuang GL, Lu LM, Zhang J, Shen Y, Chen HZ, Zhu L.   +9 more
europepmc   +1 more source

NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers. [PDF]

Cell Death Dis, 2018
Wang X, Yin H, Zhang H, Hu J, Lu H, Li C, Cao M, Yan S, Cai L.   +8 more
europepmc   +1 more source

Persistent TOP1 cleavage complexes in drug-tolerant cells drive adaptive resistance to EGFR-targeted therapies in lung cancer. [PDF]

Sci Adv
Geraud M, Gence R, Casanova A, Taranchon-Clermont E, Salimbeni S, Özsu N, Vienne M, Delahaye C, Borrull E, Lusque A, Morisseau M, Filleron T, Pagan D, Taha C, Cristini A, Mazières J, Calvayrac O, Favre G, Pradines A, Sordet O.   +19 more
europepmc   +1 more source

Comparative metabolomic analysis of HPAC cells following the acquisition of erlotinib resistance. [PDF]

Oncol Lett, 2017
Lee S, Jang WJ, Choi B, Joo SH, Jeong CH.   +4 more
europepmc   +1 more source

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase. [PDF]

Theranostics, 2018
Dong JK, Lei HM, Liang Q, Tang YB, Zhou Y, Wang Y, Zhang S, Li WB, Tong Y, Zhuang G, Zhang L, Chen HZ, Zhu L, Shen Y.   +13 more
europepmc   +1 more source

Combination AURKA and WEE1 Inhibition Exhibits Efficacy in EGFR or Pan-ERBB Inhibitor-Resistant Head and Neck Squamous Cell Carcinoma. [PDF]

Cancer Res Commun
Silva FN, Lee JW, Nguyen TT, Goeckel FM, Bagnyukova T, Borghaei H, Golemis EA, Burtness BA.   +7 more
europepmc   +1 more source

Nanoplatforms for EGFR-TKI resistance reversion and immunoactivation in NSCLC by ER stress and siRNA intervention. [PDF]

J Nanobiotechnology
Qu Y, Jiang Y, Zhu Z, Dai Y, Wang W, Li Z, Ma L, Sun Y, Liu D, Ma Y, Han W, Xu W, Shi J, Kong X.   +13 more
europepmc   +1 more source